Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lutikizumab · A-1234138, ABT-981

Bispecific antibody · Antagonist of Interleukin-1 alpha (IL1A) and Interleukin-1 beta (IL1B) · developed by AbbVie

Phase 2 Most advanced trial

ABBV Developer

1 Registered trials

What is Lutikizumab?

Lutikizumab is a dual-variable domain IgG1 antibody that binds and neutralizes interleukin-1 alpha and beta. It is being studied in rheumatoid arthritis to reduce inflammation, pain, and structural progression.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: A-1234138, ABT-981
Drug type: Bispecific antibody
Targets: Interleukin-1 alpha (IL1A), Interleukin-1 beta (IL1B)
Mechanism: Antagonist of Interleukin-1 alpha (IL1A) and Interleukin-1 beta (IL1B)
Pathways: inflammatory response inhibition
Therapy area: Immunology, Musculoskeletal
Developer: AbbVie (ABBV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 15FAZ725S0

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06972446	Phase 2	Rheumatoid Arthritis	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

Other drugs acting on IL1A / IL1B

Hutrukin Phase 1 Natrunix Phase 2 Vilamakitug Phase 2

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Lutikizumab

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z